Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Development of an automated capillary nano-immunoassay-Simple Western assay-to quantify total TDP43 protein in human platelet samples.

Authors:
Anthony Fourier Jean Escal Emilien Bernard Ingolf Lachman Armand Perret-Liaudet Pascal Leblanc Isabelle Quadrio

Anal Bioanal Chem 2019 Jan 29;411(1):267-275. Epub 2018 Oct 29.

Neurochemistry Laboratory, Biochemistry Department, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, 59 Bd Pinel, 69677, Bron, France.

Frontotemporal lobar degeneration syndrome is the second cause of young-onset dementia. Unfortunately, reliable biomarkers are currently lacking for the diagnosis of this disease. As TDP43 protein is one of the proteins pathologically involved in frontotemporal lobar degeneration, many studies have been performed to assess TDP43 protein diagnostic performances. Mixed results were obtained using cerebrospinal fluid and plasma samples so far. The aim of the study was to develop an automated capillary nano-immunoassay-Simple Western assay-to detect and quantify TDP43 protein simultaneously in human blood-based samples. Simple Western assay was developed with two different cell lysates used as positive controls and was compared to Western blot. TDP43 protein profiles in plasma samples were disappointing, as they were discordant to our positive controls. On the contrary, similar TDP43 patterns were obtained between platelet samples and cell lysates using both assays. Simple Western assay provided good quantitative performances in platelet samples: a linearity of signals could be observed (r = 0.994), associated to a within-run variability at 5.7%. Preliminary results based on a cohort of patients suffering from frontotemporal lobar degeneration showed large inter-individual variations superior to Simple Western's analytical variability. Simple Western assay seems to be suitable for detecting and quantifying TDP43 protein in platelet samples, providing a potential candidate biomarker in this disease. Further confirmation studies should now be performed on larger cohorts of patients to assess diagnostic performances of TDP43 protein in platelet samples.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00216-018-1437-4DOI Listing
January 2019

Publication Analysis

Top Keywords

tdp43 protein
28
platelet samples
20
frontotemporal lobar
12
simple western
12
western assay
12
lobar degeneration
12
samples
8
diagnostic performances
8
protein platelet
8
positive controls
8
plasma samples
8
tdp43
8
studies performed
8
cell lysates
8
western assay-to
8
capillary nano-immunoassay-simple
8
automated capillary
8
nano-immunoassay-simple western
8
protein
7
western
6

Altmetric Statistics


Show full details
3 Total Shares
1 News Outlets
2 Tweets
3 Citations

Similar Publications

High-throughput Flow Cytometry Assay to Investigate TDP43 Splicing Function.

Authors:
H Broder Schmidt Rajat Rohatgi

Bio Protoc 2020 Apr 20;10(8):e3594. Epub 2020 Apr 20.

Department of Biochemistry, Stanford University School of Medicine, Stanford, USA.

Mutations in RNA-binding proteins (RBPs) such as TDP43 are associated with transcriptome-wide splicing defects and cause severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The impact of RBP mutations on splicing function is routinely studied using PCR-based bulk measurements. However, the qualitative and low-throughput nature of this assay make quantitative and systematic analyses, as well as screening approaches, difficult to implement. Read More

View Article and Full-Text PDF
April 2020
Similar Publications

Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation.

Authors:
Paraskevi Tziortzouda Ludo Van Den Bosch Frank Hirth

Nat Rev Neurosci 2021 Mar 2. Epub 2021 Mar 2.

Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Cytoplasmic aggregation of TAR DNA-binding protein 43 (TDP43; also known as TARDBP or TDP-43) is a key pathological feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP43 typically resides in the nucleus but can shuttle between the nucleus and the cytoplasm to exert its multiple functions, which include regulation of the splicing, trafficking and stabilization of RNA. Cytoplasmic mislocalization and nuclear loss of TDP43 have both been associated with ALS and FTD, suggesting that calibrated levels and correct localization of TDP43 - achieved through an autoregulatory loop and tightly controlled nucleocytoplasmic transport - safeguard its normal function. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Concomitant gain and loss of function pathomechanisms in C9ORF72 amyotrophic lateral sclerosis.

Authors:
Arun Pal Benedikt Kretner Masin Abo-Rady Hannes Glaβ Banaja P Dash Marcel Naumann Julia Japtok Nicole Kreiter Ashutosh Dhingra Peter Heutink Tobias M Böckers René Günther Jared Sterneckert Andreas Hermann

Life Sci Alliance 2021 04 22;4(4). Epub 2021 Feb 22.

Translational Neurodegeneration Section "Albrecht-Kossel," Department of Neurology, and Center for Transdisciplinary Neuroscience (CTNR), University Medical Center Rostock, University of Rostock, Rostock, Germany

Intronic hexanucleotide repeat expansions (HREs) in are the most frequent genetic cause of amyotrophic lateral sclerosis, a devastating, incurable motoneuron (MN) disease. The mechanism by which HREs trigger pathogenesis remains elusive. The discovery of repeat-associated non-ATG (RAN) translation of dipeptide repeat proteins (DPRs) from HREs along with reduced exonic C9ORF72 expression suggests gain of toxic functions (GOFs) through DPRs versus loss of C9ORF72 functions (LOFs). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Amyotrophic Lateral Sclerosis (ALS) prediction model derived from plasma and CSF biomarkers.

Authors:
Radhika Khosla Manjari Rain Suresh Sharma Akshay Anand

PLoS One 2021 19;16(2):e0247025. Epub 2021 Feb 19.

Department of Neurology, Neuroscience Research Lab, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder of motor neurons which leads to complete loss of movement in patients. The only FDA approved drug Riluzole provides only symptomatic relief to patients. Early Diagnosis of the disease warrants the importance of diagnostic and prognostic models for predicting disease and disease progression respectively. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression.

Authors:
Júlia Canet-Pons Nesli-Ece Sen Aleksandar Arsović Luis-Enrique Almaguer-Mederos Melanie V Halbach Jana Key Claudia Döring Anja Kerksiek Gina Picchiarelli Raphaelle Cassel Frédérique René Stéphane Dieterlé Nina V Fuchs Renate König Luc Dupuis Dieter Lütjohann Suzana Gispert Georg Auburger

Neurobiol Dis 2021 Feb 10;152:105289. Epub 2021 Feb 10.

Experimental Neurology, Medical Faculty, Goethe University, 60590 Frankfurt am Main, Germany. Electronic address:

Large polyglutamine expansions in Ataxin-2 (ATXN2) cause multi-system nervous atrophy in Spinocerebellar Ataxia type 2 (SCA2). Intermediate size expansions carry a risk for selective motor neuron degeneration, known as Amyotrophic Lateral Sclerosis (ALS). Conversely, the depletion of ATXN2 prevents disease progression in ALS. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap